Overactive bladder (OAB) is a condition characterized by involuntary bladder contractions. Antimuscarinic drugs are commonly used to treat OAB by blocking muscarinic receptors (M2 and M3) in the bladder. These same receptors are also present in the seminal vesicles and vas deferens, which are structures involved in ejaculation.
This observational study aims to evaluate whether antimuscarinic drugs used for OAB treatment have any effect on ejaculation duration and the refractory period in male patients. Male patients aged 20-50 who are prescribed antimuscarinic medication (tolterodine, propiverine) for OAB will complete validated questionnaires (IIEF, PEP, PEDT, OAB-V8) before starting treatment and at 1-month and 2-month follow-up visits. No changes will be made to the patients' standard treatment.
Inclusion Criteria:
Exclusion Criteria:
Male patients aged 20-50 with overactive bladder who are initiated on tolterodine as part of standard clinical care. Participants complete IIEF, PEP, PEDT, and OAB-V8 questionnaires at baseline, 1-month, and 2-month follow-up visits. No modification to standard treatment is performed.
Male patients aged 20-50 with overactive bladder who are initiated on propiverine as part of standard clinical care. Participants complete IIEF, PEP, PEDT, and OAB-V8 questionnaires at baseline, 1-month, and 2-month follow-up visits. No modification to standard treatment is performed.
Male patients aged 20-50 with overactive bladder who are initiated on mirabegron as part of standard clinical care. Participants complete IIEF, PEP, PEDT, and OAB-V8 questionnaires at baseline, 1-month, and 2-month follow-up visits. No modification to standard treatment is performed.
Istanbul, Istanbul 34200, Turkey (Türkiye)
Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP
A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring